-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13.5

Benzinga·04/09/2026 10:54:10
Listen to the news
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13 to $13.5.